Solo-Dex, Inc., a U.S.-based medical device innovator, and Polymedicure Ltd. (Polymed), Indias leading manufacturer of high-quality medical devices, today announced a strategic manufacturing and supply partnership to bring Solo-Dexs patented, opioid-free regional anesthesia solutions to hospitals across India for the first time.
Under this agreement, Polymed will manufacture Solo-Dexs flagship product, the Fascile Continuous Peripheral Nerve Block system, in accordance with Solo-Dexs strict quality standards, for distribution across India and key global markets. The product is already approved for clinical use in the United States and Europe and is now set to support Indias expanding Enhanced Recovery After Surgery (ERAS) programs and the growth of outpatient surgical care.
“This is a game-changer for pain management in India,” said Steven Eror, CEO of Solo-Dex. “Polymeds scale, precision, and strong regulatory framework make them the ideal manufacturing partner. Together, well deliver a transformative technology that goes far beyond suppressing pain-it blocks acute pain completely.”
First-of-its-kind in India: Faster, Safer, Non-Opioid Pain Control
Solo-Dexs patented device installs in under two minutes and enables continuous, localized pain relief without opioids. Unlike conventional methods that may require IV sedation and can result in patient delirium, Solo-Dex minimizes systemic drug exposure, and eliminates the need for oral opioids thereby improving patient safety, reducing recovery time, and decreasing demand on hospital resources.
The technology is designed to seamlessly integrate with ERAS protocols, helping hospitals manage post-operative pain more efficiently. As Indias healthcare system increasingly embraces day surgery and outpatient models, Solo-Dex offers a solution that enhances patient throughput and satisfaction without compromising clinical outcomes.
“We are excited to be part of this international collaboration,” said Himanshu Baid, Managing Director of Polymed. “This partnership not only brings cutting-edge pain management to Indian clinicians and patients, but also aligns with our commitment to making world-class healthcare more accessible.”
Designed for Global Impact
Manufacturing will take place in Polymeds ISO 13485-certified, FDA-auditable facilities, with initial orders for 100,000 units. In addition to serving India, the partnership aims to fulfill international demand across Asia, Africa, Latin America, and select European markets, with Solo-Dex overseeing global regulatory compliance and branding.
“Thanks to this agreement, Solo-Dex now has the scalable, cost-effective production capacity to meet global demand while maintaining the clinical precision and quality our technology requires,” said Eror. “Were especially proud to collaborate with Polymed to address the worldwide need for safer, opioid-free surgical recovery.”
The Solo-Dex and Polymed partnership is already engaging with leading hospital systems across India, with commercial availability expected to begin in Q4 2025.
About Solo-Dex, Inc.
Solo-Dex is a U.S.-based medical device company focused on opioid-free acute pain management. Its patented continuous peripheral nerve block systems enable anesthesiologists to deliver localized, long-lasting anesthesia for post-surgical recovery. Solo-Dex technology is approved for clinical use in the U.S. and EU.
About Polymedicure Limited
Polymed is one of Indias most trusted names in medical devices, with a portfolio of more than 125 FDA-approved and CE-marked products. With a global presence in over 100 countries, Polymed operates high-end manufacturing facilities and is committed to delivering innovative, high-quality healthcare solutions at scale.
